|LE Magazine March 2000|
Overlooked & Overworked
Preventive maintenance for your stomach, liver and pancreas
by Karin Granstrom Jordan, MD
A European soy derivative helps protect vital organs from the effects of toxic overload, obesity, alcohol, aspirin and NSAIDs-and helps maintain a youthful cholesterol profile.
The aging process, combined with deleterious lifestyle habits, inflicts tremendous damage on our vital organs. NSAIDs and aspirin are toxic to the gut, while alcohol is toxic to the liver and pancreas. Our poor diets too often stress the organs of digestion and metabolism, while contributing to the buildup of arterial plaques. The modern diet and alcohol consumption can also lead to obesity that further promotes liver pathology and cardiovascular disease. One of the best things you can do for your future health is to support and optimize the function of the vital organs compromised by those interrelated stressors-the stomach, liver, pancreas and cardiovascular system.
PPC Soy derivative
Phosphatidylcholine (the main component of lecithin) is an integral part of cell membranes, essential for their structural and functional integrity. Cell membranes act like gatekeepers, allowing nutrients into the cells but blocking damaging toxins from gaining entrance. A new extract from soybeans called PPC (polyenylphosphatidylcholine) has been shown to enhance cell membrane function throughout the body.
PPC is approved for the treatment of chronic liver diseases in many European countries and is actually listed in the Physician's Desk Reference (PDR) of the United States. An accumulating body of research suggests that PPC's umbrella of protection may extend from the liver to the stomach, pancreas and cardiovascular system. PPC is well absorbed in humans and animals when taken orally. There are no known contraindications, side effects or interactions with other drugs, even with consumption of large quantities of PPC.
It is believed that PPC's protective effect is based on its ability to be incorporated into normal and damaged cell membranes. Animal studies have indicated that PPC, which is a polyunsaturated phosphatidylcholine, becomes incorporated into the membranes of liver cells as a substitute for native saturated phosphatidylcholine molecules (Stoffel W et al 1978). This substitution is shown to result in an increase in membrane fluidity and active transport activity across the membrane. Similarly, PPC is incorporated into blood lipoproteins such as cholesterol, leading to lipid-lowering properties.
The consumption of non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin in our society is greater than any other drug class because of their relative effectiveness in the treatment of pain and inflammation. Recently published evidence shows that those who take NSAIDs have lower risks of Alzheimer's disease, cardiovascular disease and certain cancers. It appears that some of the common diseases of aging are caused by a chronic inflammatory cascade and that daily NSAID ingestion affords considerable protection against these disorders.
A major concern with NSAID drugs, though, relates to their well-established ability to induce gastrointestinal injury in the forms of erosion, bleeding, ulceration and perforation. Few people realize that GI toxicity from NSAIDs is the most frequent adverse drug event in the U.S., according to some estimates. The facts are alarming (Raskin JB, 1999; Wolfe MM et al., 1999):
- NSAIDs are used regularly by at least 13 million Americans with arthritic conditions, leading to 16,500 NSAID-related deaths annually (similar to the number of deaths from AIDS).
- NSAID use increases the relative risk of serious gastrointestinal events three-to-fourfold, and higher for the elderly.
- 30-60% of chronic NSAID users develop gastroduodenal erosions; 5-30% of chronic users develop ulcers.
- One third of patients over age 60 with bleeding from peptic ulcers are on NSAIDs.
- Two thirds of patients over age 60 with GI perforations are on NSAIDs.
- Over 100,000 people are hospitalized annually in the U.S. for serious GI complications from NSAID use.
- The mortality rate for patients hospitalized for upper GI bleeding from NSAIDs is 5-10%.
- GI toxicity from NSAID use is the 15th most common cause of death in the U.S.
- Advanced age is a primary risk factor for adverse GI events from NSAID use, and the risk increases steadily with age.
This "silent epidemic" appears without symptoms in up to 40% of cases of NSAID-induced erosive gastritis. While 10-20% of NSAID users have indigestion (dyspepsia), this is not a reliable indicator of mucosal injury. Damage to the gastric epithelium begins within minutes of taking an NSAID, and hemorrhages and erosions follow within hours. In most people the gastric mucosa adapt over time, but studies show that 60-100% of patients on NSAIDs for 1 to 2 weeks develop submucosal hemorrhage, superficial erosions, erythema (inflammation of mucous membranes), or blood in the stool. Moreover, NSAID toxicity extends to the small intestine and large bowel, as manifested in silent ulcerations, colitis-like conditions, and aggravation of inflammatory bowel disease.
Doses of aspirin as low as 30 mg suppress the production of protective prostaglandins in the gastric mucosa. In addition, aspirin's direct contact with the gastrointestinal tract interferes with the hydrophobic "non-wettable" properties that protect the underlying epithelium from gastric acid and other toxic substances. This characteristic seems to be attributable to an extracellular lining of phospholipids, which are synthesized in surface mucus cells of the stomach. Aspirin and other NSAIDs can rapidly transform the gastric mucosa from a non-wettable to a wettable state, thereby increasing the tissue's susceptibility to the corrosive actions of gastric acid.
A study on experimentally induced gastric ulcers in rats (Dunjic BS, et al., 1993) showed that mucosal lesions were significantly reduced by a single dose of PPC given before or after the injury factor, which in this study was ethanol or an NSAID.
A recent clinical trial compared the GI effects of aspirin to those of aspirin complexed with PPC (Anand BS et al., 1999). Sixteen healthy subjects were given either ten doses of aspirin or ten doses of the aspirin/PPC complex over a 72 hour period. After a "washout" period, subjects were switched over to the other medication for a 72 hour period.
Researchers counted the number of gastroduodenal erosions in each subject. Those taking aspirin had an average of 8.75 erosions, while those taking the aspirin/PPC complex averaged only 2.81 erosions. The protective effect of PPC was most apparent in those who were most susceptible to aspirin injury, and did not interfere with the therapeutic activity of the aspirin.
(Editors note: The cardio-protective benefits of aspirin are substantial. In addition to reducing abnormal arterial blood clot formation, aspirin suppresses a dangerous pro-inflammatory agent called C-reactive protein. The latest finding about heart attack risk shows that C-reactive protein causes a lethal inflammatory cascade on the inner arterial wall. What happens is that C-reactive protein induces atherosclerotic plaque on the arterial wall to burst open like popcorn, blocking a coronary artery and causing a heart attack. Aspirin specifically suppresses C-reactive protein. Now that PPC supplements are available, taking low-dose aspirin can be made a lot safer for those who take it as a preventive.)
Cholesterol and angina reduction
PPC's beneficial effects on blood lipoproteins have been demonstrated in a series of animal and human studies. A clinical trial conducted in St. Petersburg, Russia, (Klimov AN et al., 1995) compared PPC to niacin in angina patients with a hereditary elevation of cholesterol and triglycerides. Niacin is considered a standard treatment for this condition, but adverse effects are fairly common. These include flushing, skin dryness and itching, GI disturbances, elevation of liver enzymes, decline in glucose tolerance, and reduced urinary excretion of uric acid.
In this study, 100 patients were randomly assigned to receive either PPC or niacin for six months. Patients in both groups were put on a low-fat cholesterol free diet, and any lipid-lowering medications they had been taking were discontinued four weeks before the start of the trial. For the first two weeks of the trial, PPC was given intravenously (500 mg/day); for the remaining five and a half months, patients took 600 mg of PPC in capsules three times a day.
Both medications reduced the frequency of angina attacks, from 2.3 per week to 0.9 in the niacin group, and from 3.8 to 0.9 in the PPC group. Eight patients (16%) in the niacin group dropped out due to adverse effects of the medication, while the patients in the PPC group were entirely free of side effects. Only the PPC group showed a significant improvement in exercise tolerance. PPC significantly reduced oxidation of apoB lipoprotein, while niacin did not. The two medications improved the overall lipoprotein profile of the patients to a similar extent. PPC lowered total and LDL cholesterol by about 15%, and triglycerides by 32%.
PPC also raised levels of the "good" HDL cholesterol by 10%. It is fortunate that the researchers looked beneath the surface of this modest increase, where they discovered a fascinating phenomenon.
HDL and longevity
It is well known that the most protective subfraction of HDL cholesterol is the one with the largest particles, known as HDL2b. When rhesus monkeys are placed on a calorie restricted diet to slow the aging process, their HDL2b levels increase significantly (Verdery RB et al., 1997). A study of centenarian women provided dramatic evidence of the cardioprotective importance of this subfraction (Barbagallo CM et al., 1998). Lipoprotein profiles of the centenarians were compared to those of healthy middle-aged and elderly women of the same weight. There were no significant differences found between the centenarians and the younger women in the battery of tests, which included plasma lipids, apolipoprotein, and Lp(a)-except in HDL2b and HDL3a levels. While the total HDL levels were about the same, HDL2b levels were significantly increased in the centenarians, and HDL3a levels were significantly decreased, compared to the other groups. The researchers call for further study of the distribution of HDL subfractions as a possible marker of longevity.
Such a major shift in the distribution of HDL subfractions-from HDL3a to HDL2b-also occurred in the PPC group of the Russian study, but not in the niacin group. Thus, while total HDL levels rose modestly after PPC supplementation, the desirable HDL2b subfraction rose preferentially due to a shift from the 2a and 3a subfractions to the highly antiatherogenic 2b subfraction. Thus PPC may exert an anti-aging effect on the cardiovascular system, a prospect meriting further research.
High serum lipids are common in diabetic patients (approx. in 50%), and the incidence of coronary heart disease is high. In a double-blind study on the lipoprotein profile in diabetic patients (Kirsten R et al., 1994), 30 non-insulin-dependent diabetics with secondary hyperlipidemia received 2.7 g PPC or placebo daily over a 2-month period. LDL-cholesterol and triglyceride levels decreased significantly when compared with the placebo group, and HDL cholesterol levels increased (see table). In the control group the values did not change throughout the trial.
Moderate alcohol intake has been shown to improve the lipoprotein profile, and especially to raise HDL cholesterol levels. A study on rats shows that PPC preserves the HDL elevating effect of alcohol, while decreasing LDL and VLDL cholesterol levels after eating (Navder KP et al., 1997).
However, higher levels of alcohol consumption are toxic to the liver, and increase oxidation of LDL cholesterol. New research on baboons shows that PPC markedly reduces alcohol-induced oxidation of LDL, thus helping to protect against one of the mechanisms that promotes atherosclerosis in heavy drinkers (Navder KP et al., 1999). At the same time, PPC helps protect the liver from alcohol toxicity.
The liver is the largest organ of the body, responsible for metabolizing the food we eat (breaking it down into useful parts) and protecting us from the damaging effects of the numerous toxic compounds that we are exposed to on a daily basis. But what protects the liver so that it can in turn protect the rest of the body? The liver is unfortunately susceptible to toxicity itself, and to an insidious condition called steatosis thought to be a precursor to many serious liver diseases. Steatosis, also called fatty liver, is a common finding in human liver biopsies. It is a condition in which fat has accumulated within liver cells (hepatocytes) without causing any specific symptoms. As we shall discuss, PPC may help correct steatosis.
Fatty liver as a longstanding chronic condition can occur in association with a wide range of diseases, toxins and drugs, although in clinical practice, the majority of cases are due to alcohol excess, diabetes and obesity. Much less common are occurrences of acute fatty liver during pregnancy and as a response to administration of tetracyclines, acetaminophen and other drugs and toxins.
Fatty liver had long been believed to be a benign reversible condition. Careful clinical studies, however, demonstrate that fatty liver of either alcoholic or non-alcoholic origin can lead to inflammation, cell death and fibrosis (steatohepatitis), and eventually even cirrhosis. Cirrhosis is the irreversible end result of fibrous scarring, a response of the liver to a variety of long-standing inflammatory, toxic, metabolic and congestive damage.
Alcohol is by far the commonest cause both of steatosis and cirrhosis in the Western world. However, there is a considerable inter-individual difference in the degree of liver damage produced by excessive alcohol intake. There seem to be no clear correlations between the incidence and severity of fatty liver and either the amount, type or duration of alcohol abuse. It has been unclear why in some individuals steatosis, whatever its etiology, never progresses to steatohepatitis and cirrhosis.
A growing body of evidence suggests that the oxidation of fat in the liver leads to the development of liver damage, and free radicals have been demonstrated to play an important role in the hepatotoxic effect of many substances. The oxidation of fats takes place through a chain reaction called lipid peroxidation that impairs the anatomical and functional integrity of membranes and creates new toxic substances that further extend the damage. PPC's antioxidant action may help explain its effectiveness in treating fatty liver, as demonstrated by a study carried out in the Czech Republic (Horejsova M and Urban J, 1994).
This Czech study of 28 women with steatosis of various origins showed PPC to be a highly effective therapy for fatty liver. The women were given PPC along with unsaturated fatty acids and low-dose B vitamins and vitamin E. After six months, ultrasound examinations revealed that eight of the women were free of apparent steatosis, 13 had improved, while the remaining seven showed no change. Abnormal enlargement of the liver (hepatomegaly) was significantly reduced, and the working tissue of the liver (parenchyma) became homogeneous in 10 of the 11 cases where it had been abnormal.
Lab tests showed highly significant declines in all of the liver enzyme levels measured (ALT, AST, GMT). There were also significant declines in bilirubin, cholesterol and triglycerides. Overall, 54% of the patients in the study improved in all parameters studied, as determined by ultrasound assessment, lab tests and subjective evaluation. Forty-three percent showed improvement in lab tests and subjective evaluation, and only 3.6% did not show any objective improvement.
Back to the Magazine Forum